Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract ...

A new modelling study reveals that only 7% of carbapenem-resistant Gram-negative (CRGN) bacterial infections in eight LMICs ...

Escalating antimicrobial resistance is a global threat, emphasizing the need to explore alternative treatment options. Hence, we aimed to explore the ...

NHS hospitals have seen a 30 per cent spike in cases of antibiotic-resistant bacteria - which can be fatal if it enters the ...

A major treatment gap for life-threatening carbapenem-resistant Gram-negative bacterial infections has been revealed across ...

Hospitals in the UK have seen a 30% spike in cases of dangerous superbugs resistant to antibiotics which has been triggered ...

Published in the Journal of Hospital Infection, the study assessed the prevalence of key AMR threats—being methicillin-resistant Staphylococcus aureus (MRSA), plus carbapenem-resistant Pseudomonas ...

Conclusion. Doripenem is an injectable carbapenem antibiotic with a spectrum of activity comparable to that of imipenem and meropenem. Its safety is similar to that of other carbapenems.

The clinical burden of carbapenem-resistant Acinetobacter baumannii has worsened across U.S. hospitals in recent years, according to a study published April 17 in BMC Infectious Diseases.

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be comple ...

I) Molecular Resistance mechanisms and Genomic characterisation. This is a mechanistic study of multi-resistant Gram-negative ...